Cellseed Inc. · TSE:7776
Cellseed — H1 2024 Earnings Presentation
35 slides from Cellseed's earnings presentation, Sep 5, 2024
Slide 1: Fiscal 2024 First-Half Earnings Results Presentation
CellSeed Inc. Fiscal 2024 First-Half Earnings Results Presentation Tokyo Stock Exchange Growth Code:7776
Slide 2: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2024 Progress of each business © 2024 CellSeed Inc. 1
Slide 3: Head office, CPC, development and manufacturing facility
Head office・CPC・development and manufacturing facility Established May, 2001 Core Cell Sheet Engineering based Telecom Center competence on Temperature Responsive Polymers Listed Tokyo Stock Exchange Growth（7776) Head Office 15F (East Wing) Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo Cell P
Slide 4: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Regenerative Medical Regenerative Medicine Products Business Supporting Business Commercialization of Cell Sheet Therapies Intellige
Slide 5: Our Business Model
Our Business Model Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partner Companies Delivering the technology developed at a university and developed at a venture to patients as soon as possible. © 2024
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering © 2024 CellSeed Inc. 5
Slide 7: New law related to regenerative medicine, enforced in 2014
New law related to regenerative medicine, enforced in 2014 Act on the Safety of Regenerative Act on Securing Quality, Efficacy and Safety of Products Including Medicine Pharmaceuticals and Medical Devices Law for regulating regenerative medicine, Law for regulating products for etc. performed on the
Slide 8: Sources of cells used for regenerative medicine
Sources of cells used for regenerative medicine Autologous Allogeneic Harvesting of Harvesting of Cells of patients cells Cells of others cells ・Somatic cells ・Somatic cells ・Mesenchymal stem ・Mesenchymal stem cells cells ・iPS cells ・iPS cells Donor Administration Administration Merits Merits • Free
Slide 9: Methods for administering products for regenerative medicine, etc.
Methods for administering products for regenerative medicine, etc. To directly administer or To administer a product to implant a product to a the entire body via blood target area for vessels by injection or regeneration by surgery intravenous drip or with an endoscope © 2024 CellSeed Inc. 8
Slide 10: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2024 Progress of each business © 2024 CellSeed Inc. 9
Slide 11: Half-year financial summary FY 12/2024
Half-year financial summary FY 12/2024 First Half of the FY2024 First Half of the FY2023 (January 2024 - June 2024) (January 2023 - June 2023) Change from Change from Amount Amount Previous Period Previous Period (Millions of yen) (Millions of yen) (Millions of yen) (%) Sales 76 9 13.9 66 Operating
Slide 12: Topics (cumulative 2nd quarter of FY 12/2024)
Topics (cumulative 2 nd quarter of FY 12/2024) The sales of cultureware increased from the previous year, because we received a healthy number of orders from an overseas agency (Thermo Fisher). In the commissioned regenerative medicine business, we recorded sales from one case like in the previous y
Slide 13: Completion of exercise of the 24th share acquisition right
Completion of exercise of the 24 th share acquisition right distributed through the allocation to third parties The exercise of the 24 th share acquisition right was completed, and then we procured a total of about 1.95 billion yen. Issuance of the 24 th share acquisition right with a provision for
Slide 14: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2024 Progress of each business © 2024 CellSeed Inc. 13
Slide 15: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell® This cultureware maintains In addition to the same the physiological activity of characteristics as those of cells and retains a high level UpCell®, this cultureware of antigen proteins on the cell allows for the recovery of sur
Slide 16: Variation in sales of the cell cultureware business
Variation in sales of the cell cultureware business Sales grew threefold in the past 7 years. In 2023, overseas sales increased significantly. In FY 12/2023, sales hit a record high. In the first half of FY 12/2024 We received a healthy number of orders from an overseas agency (Thermo Fisher). Sales
Slide 17: Overseas needs for cell cultureware
Overseas needs for cell cultureware Regenerative medicine outside Japan: Trends of fundamental research, clinical study, and therapy There are an increasing number of treatments for cancer, allergy, and immunity disorder and treatments using stem cells. Major purposes of overseas UpCell users: Cultu
Slide 18: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Need for technology to culture cells in large quantities Biopharmaceutical manufacturing Possibility of Manufacturing cells for use in immunotherapy market expansion Development of cellular foods such as cultured meat Required number of cells Cul
Slide 19: Regenerative medicine supporting business: Regenerative medicine consignment services
Regenerative medicine supporting business: Regenerative medicine consignment services © 2024 CellSeed Inc. 18
Slide 20: Regenerative medicine consignment services
Regenerative medicine supporting business: Regenerative medicine consignment services Serving as a bridge to deliver regenerative medicine to patients by solving problems with academia and closing the gap Acquisition of licenses for manufacturing and sale in accordance with the Act on R&D in academi
Slide 21: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business 1 Development of Manufacturing Methods and Contract Manufacturing for Cell Sheet Products Development of cell sheet manufacturing methods Contract manufacturing of cell sheet products Quality testing of cell sheets, etc. 2 Facility Management and Appli
Slide 22: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service Cell Processing Center The permission to manufacture specific processed cells (facility No. FA3160008 , March 2017) The permission to manufacture products for regenerative medicine（October 2018 ） Major commissioned project results Auto
Slide 23: Background for development of allogeneic cartilage cell sheets (CLS2901C)
Background for development of allogeneic cartilage cell sheets (CLS2901C) Knee osteoarthritis (OA) Due to the aging of the population, the number of patients is projected to increase. In clinical research, good results There is no definitive treatment method. were observed in all of 10 cases.
Slide 24: Manufacturing process of allogeneic cartilage cell sheets (CLS2901C)
Manufacturing process of allogeneic cartilage cell sheets (CLS2901C) Cell Bank Fingers removed from polydactyly patients Isolated cartilage Seeding Cryopreservation Passage culture P0 P1 Cell Stock (Master Cell Bank) Px Working Cell Bank Safety Safety Safety Cell Sheets Transplant Preculture Sheet f
Slide 25: Quality test items for cell banks and cell sheets
Quality test items for cell banks and cell sheets Tests for cell count, ratio of living cells, aseptic conditions, endotoxin, Cell Bank response to mycoplasma and viruses, etc. Fingers removed from polydactyly patients Isolated cartilage Seeding Cryopreservation Passage culture P0 P1 Cell Stock (Mas
Slide 26: Third-phase test of allogeneic cartilage cell sheets
Third-phase test of allogeneic cartilage cell sheets Subjects: patients with knee osteoarthritis who should undergo high tibial osteotomy (HTO) Flowchart of treatments 1 month after an operation and thereafter 1 year after an operation Discharge Implant Registration Exam, etc. Operation from hospita
Slide 27: U.S. patent related to allogeneic cartilage cell sheets
U.S. patent related to allogeneic cartilage cell sheets In response to the application for the following U.S. patent related to allogeneic cartilage cell sheets, a decision to grant a patent has been made. U.S. patent application No. 17/729,608 Title of the invention: a cultured cell sheet for t
Slide 28: Exhibitions, research presentations, etc. at academic conferences in 2024
Exhibitions, research presentations, etc. at academic conferences in 2024 The Japan Society for Immunology (poster presentation and corporate exhibition; Mar. 28- 30, 2024) The Japanese Society for Regenerative Medicine (luncheon, poster, and corporate exhibition; Mar. 28-30, 2024) The Pharmaceutica
Slide 29: Participation in academic conferences, etc.
Participation in academic conferences, etc. Congress of the Japanese Society for Regenerative Medicine Date: Thursday, March 21 to Saturday, March 23 Place: Toki Messe (Niigata) Corporate exhibition Co-hosted academic seminar © 2024 CellSeed Inc. 28
Slide 30: Participation in academic conferences, etc.
Participation in academic conferences, etc. Japanese Research Group on Knee Osteotomy and Joint Preservation Date: Friday, April 19 to Saturday, April 20 Place: Rexxam Hall (Takamatsu) Co-hosting lectures for citizens © 2024 CellSeed Inc. 29
Slide 31: Participation in academic conferences, etc.
Participation in academic conferences, etc. Regenerative Medicine EXPO Date: Wednesday, June 26, 2024; 14:00 to 15:00 Place: Tokyo Big Sight Special lecture 2 at Regenerative Medicine EXPO Round-table talk: regarding regulations on all phases from clinical trials to after-sales care for products f
Slide 32: Participation in academic conferences, etc.
Participation in academic conferences, etc. ISSCR 2024 Date: Wednesday, July 10 to Saturday, July 13 Place: Hamburg, Germany Poster presentation Potential marker extraction to predict an efficacy of allogeneic chondrocyte cell sheet on knee cartilage regeneration © 2024 CellSeed Inc. 31
Slide 33: We will participate in Regenerative Medicine JAPAN
We will participate in Regenerative Medicine JAPAN Date: Wednesday, October 9 to Friday, October 11, 2024 Venue: Pacifico Yokohama Exhibition booth: Booth No. R-24 Presentation Date: Thursday, October 10; 15:40 to 15:50 Place: Regenerative Medicine Stage Presenter: Chikako Sato, Head of Cell She
Slide 34: Cell Sheet Engineering Innovation Forum
Cell Sheet Engineering Innovation Forum In 2025, we plan to hold the 4 th Cell Sheet Engineering Innovation Forum! We will inform you of details as soon as they are determined. © 2024 CellSeed Inc. 33
Slide 35: Presentation made solely for disclosure of financial statements
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. © 2024 CellSeed Inc. 34